ArticleTranslational cancer research2026
Integrating single-cell and spatial transcriptomics to decipher the neuro-immune microenvironment of breast cancer brain metastasis: a key regulatory axis, prognostic model, and drug discovery.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer brain metastasis (BCBM) is a lethal complication of advanced disease, facilitated by a specialized neuro-immune microenvironment, whereas its molecular regulators and spatial dynamics remain poorly understood. This study aimed to resolve cellular heterogeneity and intercellular signaling networks crosstalk in BCBM microenvironment by using integrated single-cell RNA sequencing (scRNA-seq) single-cell and spatial transcriptomics to identify key regulators, build a prognostic model, and computationally screen for potential therapies. Methods: We analyzed public scRNA-seq and 10× Visium spatial transcriptomics datasets. Cell landscapes were resolved with Seurat, communication networks were inferred with CellChat, and spatial mapping was performed with Tangram. A prognostic risk model was developed from bulk RNA sequencing (RNA-seq) data from The Cancer Genome Atlas-Breast Cancer (TCGA-BRCA), the Gene Expression Omnibus (GEO) datasets using Least Absolute Shrinkage and Selection Operator-Cox (LASSO-Cox) regression and validated in an independent cohort. Potential small-molecule inhibitors were screened by molecular docking (AutoDock Vina) against AlphaFold-predicted target structures. Results: The BCBM microenvironment exhibited high heterogeneity, with macrophages serving as the central signaling hub. A novel regulatory axis, interleukin-18 and myosin light chain kinase ( Conclusions: This study delineates the neuro-immune landscape of BCBM progression and proposes the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.